Advertisement
RVTY vs TMO
Which Stock Would AI Choose? Revvity (RVTY) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Both RVTY and TMO operate in the diagnostics and research sector, with overlapping exposure to life sciences tools and reagents.
- RVTY reported Q1 2026 results in early May with adjusted EPS beating estimates and announced plans to divest its China immunodiagnostics business.
- TMO is scheduled to report Q2 2026 earnings on July 23, with consensus expectations for revenue of $11.68 billion and EPS of $5.71.
- Over the past 12 months, RVTY delivered approximately +15% return compared to +25% for TMO.
- RVTY trades at a higher trailing P/E ratio (around 48-53) versus TMO (around 26), reflecting differences in scale and growth profiles.
- Sector headwinds such as China exposure and organic growth rates of 3-4% for RVTY contrast with TMO’s broader diversification and larger market capitalization.
Introduction
Revvity (RVTY) and Thermo Fisher Scientific (TMO) are two established players in the life sciences and diagnostics industry. Investors and traders seeking exposure to healthcare tools, reagents, and analytical instruments often evaluate these names together due to their comparable end markets and sensitivity to research funding cycles, biopharma spending, and regulatory environments. This comparison highlights differences in scale, recent financial results, valuation, and positioning that may influence relative performance in the current market environment.
Revvity Overview and Recent Performance
Revvity, Inc. provides life science technologies, including instruments, reagents, and software for academic, government, pharmaceutical, and clinical research applications. In recent weeks, the stock has reflected mixed sentiment following the company’s May 5, 2026, release of first-quarter results. Revenue reached $711 million with 3% organic growth on a pro forma basis, while adjusted EPS of $1.06 exceeded consensus estimates. Management updated full-year 2026 guidance to pro forma revenue of $2.81–$2.84 billion and pro forma organic growth of 3%–4%, alongside an announcement of intent to divest the China immunodiagnostics business. These factors have shaped recent trading activity within a broader sector that continues to navigate post-pandemic normalization and regional market dynamics.
Thermo Fisher Scientific Overview and Recent Performance
Thermo Fisher Scientific Inc. is a global leader in serving science, offering analytical instruments, laboratory equipment, reagents, and contract research and manufacturing services. In recent market activity, attention has centered on the company’s upcoming second-quarter earnings release scheduled for July 23, 2026, with analyst consensus pointing to revenue of approximately $11.68 billion and EPS of $5.71. The larger scale and diversified portfolio have supported relatively steadier performance compared with smaller peers. Over the trailing twelve months, TMO shares have posted gains exceeding those of RVTY, reflecting investor preference for established platforms amid ongoing industry consolidation and research spending patterns.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots drawn from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions—based on backtested statistics, win rates, drawdowns, and consistency—earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and ticker universes, with performance metrics that can vary widely depending on volatility regimes and asset classes. Traders interested in automated strategies may explore the full range of options directly on the platform.
Head-to-Head Comparison
Revvity and Thermo Fisher Scientific share exposure to the diagnostics and research sector yet differ markedly in business model and scale. TMO operates a substantially larger platform with broader geographic and product diversification, including contract services that provide recurring revenue streams. RVTY maintains a more focused portfolio, recently adjusting its China footprint through divestiture plans that could reduce certain regional risks while potentially narrowing near-term revenue. Valuation metrics show RVTY carrying a higher P/E ratio, consistent with a smaller market capitalization and differing growth expectations. Recent momentum has favored TMO on a twelve-month basis, though both names remain sensitive to biopharma capital expenditure trends and global research funding. Trade-offs include TMO’s greater stability versus RVTY’s potential for sharper moves tied to portfolio optimization.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative positioning within the sector, Tickeron’s AI models currently assign a modestly higher probability of favorable near-term momentum to TMO. Its larger scale, diversified revenue base, and stronger trailing twelve-month performance contribute to this probabilistic assessment, though outcomes remain subject to upcoming earnings results and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVTY is a Hold and TMO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 2 FA rating(s) are green whileTMO’s FA Score has 2 green FA rating(s).
- RVTY’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- RVTY’s TA Score: 5 bullish, 4 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а +1.38% price change this week, while TMO (@Medical Specialties) price change was +5.36% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.41%. For the same industry, the average monthly price growth was +2.73%, and the average quarterly price growth was +1.69%.
Reported Earning Dates
RVTY is expected to report earnings on Aug 04, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (-1.41% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| RVTY | TMO | RVTY / TMO | |
| Capitalization | 12.6B | 213B | 6% |
| EBITDA | 773M | 11.7B | 7% |
| Gain YTD | 17.208 | -1.034 | -1,665% |
| P/E Ratio | 54.41 | 30.80 | 177% |
| Revenue | 2.9B | 45.2B | 6% |
| Total Cash | N/A | 1.12B | - |
| Total Debt | 3.35B | 43.2B | 8% |
RVTY | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 76 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 89 | 62 | |
PRICE GROWTH RATING 1..100 | 43 | 45 | |
P/E GROWTH RATING 1..100 | 24 | 32 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is in the same range as RVTY (15). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as RVTY (100). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as RVTY (89). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (43) in the Medical Specialties industry is in the same range as TMO (45). This means that RVTY’s stock grew similarly to TMO’s over the last 12 months.
RVTY's P/E Growth Rating (24) in the Medical Specialties industry is in the same range as TMO (32). This means that RVTY’s stock grew similarly to TMO’s over the last 12 months.
| RVTY | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | 2 days ago 64% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 54% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 65% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 61% |
| Advances ODDS (%) | 2 days ago 64% | 2 days ago 61% |
| Declines ODDS (%) | 5 days ago 67% | 4 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 59% |
Advertisement
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | +2.38% | ||
| TMO - RVTY | 70% Closely correlated | +8.71% | ||
| WAT - RVTY | 66% Closely correlated | +3.13% | ||
| A - RVTY | 65% Loosely correlated | +4.71% | ||
| CRL - RVTY | 65% Loosely correlated | +4.84% | ||
| IQV - RVTY | 64% Loosely correlated | +4.43% | ||
More | ||||